These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8429309)

  • 1. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
    Deffond D; Durif F; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):101-3. PubMed ID: 8429309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
    Montastruc JL; Rascol O; Senard JM; Gualano V; Bagheri H; Houin G; Lees A; Rascol A
    Clin Neuropharmacol; 1991 Oct; 14(5):432-7. PubMed ID: 1742752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
    Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):385-393. PubMed ID: 38578533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
    Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
    J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sublingual apomorphine in Parkinson's disease.
    Durif F; Deffond D; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1990 Dec; 53(12):1105. PubMed ID: 2292708
    [No Abstract]   [Full Text] [Related]  

  • 8. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
    Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
    J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations.
    Hughes AJ; Webster R; Bovingdon M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1991 Dec; 14(6):556-61. PubMed ID: 1773424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between clinical efficacy and pharmacokinetic parameters after sublingual apomorphine in Parkinson's disease.
    Durif F; Paire M; Deffond D; Eschalier A; Dordain G; Tournilhac M; Lavarenne J
    Clin Neuropharmacol; 1993 Apr; 16(2):157-66. PubMed ID: 8477411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
    Merello M; Leiguarda R
    Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine in the diagnosis and treatment of parkinsonian tremor.
    Hughes AJ; Lees AJ; Stern GM
    Clin Neuropharmacol; 1990 Aug; 13(4):312-7. PubMed ID: 2208183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.